medigraphic.com
ISSN 1527-3172 (Electronic)

2022, Number 3-4

<< Back Next >>

MEDICC Review 2022; 24 (3-4)

Epidemiological Characterization of Patients in the First Eight Weeks Following Detection of SARS-CoV-2 B.1.1.529 (omicron) Variant in Cuba

Pérez-Santos L, Kourí-Cardellá V, Tejero-Suárez Y, Macías-Roig LM, Pintos-Saavedra Y, Medero-Díaz D, Figueredo-Amador C, Naranjo-González C, Morales-Arredondo D, Tamayo-Pérez NE, Martínez-Montesino Y, López-Almaguer Y, de Armas-Fernández JR, Portal-Miranda JA, Guzmán-Tirado MG

Language: English
References: 29
Page:
PDF size: 403.64 Kb.


ABSTRACT

INTRODUCTION In November 2021, omicron—a new SARSCoV- 2 variant—was identifi ed in South Africa and almost immediately, WHO declared it a ‘variant of concern’. In view of its rapid worldwide spread and its imminent introduction in Cuba, genomic surveillance was strengthened.
OBJECTIVE Describe cases during the fi rst eight epidemiological weeks (epiweeks) of SARS-CoV-2 infection attributable to omicron variant in Cuba by clinical and epidemiological variables.
METHODS From epiweek 48, 2021 to epiweek 4, 2022, 288 nasopharyngeal swabs were processed for sequencing of a 1836 bp fragment of the S gene. Variants were identified according to GISAID database and confi rmed by phylogenetic analysis. Variants’ association with clinical and epidemiological outcomes was assessed.
RESULTS The fi rst cases of omicron variant were imported, mostly from African countries and the United States. During the period studied, omicron was detected in 83.0% (239/288) of cases processed, while the delta variant was found in 17.0% (49/288). Most persons infected with omicron were symptomatic (63.2%; 151/239) and fully vaccinated (65.3%; 156/239); severe cases and deaths occurred mainly among patients aged ≥65 years (92.9%; 13/14), and 12 of these deaths occurred in fully vaccinated persons (92.3%; 12/13). Omicron spread rapidly throughout the country (from 10% of cases in epiweek 48, 2021, to 100% by epiweek 4, 2022), displacing the formerly predominant delta variant.
CONCLUSIONS Omicron’s rapid expansion in Cuba was associated with increased incidence but not with a higher case fatality rate. The relatively milder disease in those infected with this variant could be infl uenced by the high vaccination coverage, along with the natural immunity acquired as a consequence of previous virus infection.


REFERENCES

  1. World Health Organization [Internet]. Geneva:World Health Organization; c2022. Activities.Tracking SARS-CoV-2 variants; 2022 [updated 2022 Jul 7; cited 2022 Feb 26]; [about 5 p.].Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

  2. World Health Organization [Internet]. Geneva:World Health Organization; c2022. News.Classifi cation of Omicron (B.1.1.529): SARSCoV-2 Variant of Concern; 2021 Nov 26 [cited2021 Dec 26]. Available at: www.who.int/news/item/26-11-2021-classification-of-omicron-%28b.1.1.529%29-sars-cov-2-variant-of-concern

  3. Fernandes Q, Inchakalody VP, Merhi M, MestiriS, Taib N, Moustafa Abo El-Ella D, et al. EmergingCOVID-19 variants and their impact onSARS-CoV-2 diagnosis, therapeutics and vaccines.Ann Med. 2022;54(1):524–40. https://doi.org/10.1080/07853890.2022.2031274

  4. Mohapatra RK, Tiwari R. Omicron (B.1.1.529)variant of SARS-CoV-2: concerns, challenges,and recent updates. J Med Virol. 2022Jun;94(6):2336–42. https://doi.org/10.1002/jmv.27633

  5. Rahimi F, Talebi Bezmin Abadi A. Omicron:a highly transmissible SARS-CoV-2 variant.Gene Rep. 2022 Jun;27:101549. https://doi.org/10.1016/j.genrep.2022.101549

  6. Sikora D, Rzymski P. COVID-19 vaccinationand rates of infections, hospitalizations,ICU admissions, and deaths in the Europeaneconomic area during autumn 2021 wave ofSARS-CoV-2. Vaccines (Basel). 2022 Mar12;10(3):437. https://doi.org/10.3390/vaccines10030437

  7. Bhattacharyya RP, Hanage WP. Challenges in inferringintrinsic severity of the SARS-CoV-2 Omicronvariant. N Engl J Med. 2022 Jun 17;386(7):e14.https://doi.org/10.1056/nejmp2119682

  8. World Health Organization [Internet]. Geneva:World Health Organization; c2022. Publications.Overview. Enhancing response to OmicronSARS-CoV-2 variant: technical brief and priorityactions for member states; 2022 Jan 21 [cited2022 Feb 20]. 28 p. Available at: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-%28b.1.1.529%29-technical-brief-and-priority-actions-for-member-states

  9. Ministry of Public Health (CU) [Internet]. Havana:Ministry of Public Health (CU); c2022. COVID-19.Variantes de SARS-CoV-2 en Cuba: motivo máspara fortalecer las medidas de aislamiento; 2021Apr 21 [cited 2022 Feb 23]; [about 4 p.]. Availableat: https://salud.msp.gob.cu/variantes-de-sars-cov-2-en-cuba-motivo-mas-para-fortalecer-las-medidas-de-aislamiento/. Spanish.

  10. Ministry of Public Health (CU) [Internet].Havana: Ministry of Public Health (CU); c2022.COVID-19. Noticias. Variante Delta: desafíose incertidumbres ante mayor incidencia deCOVID-19; 2021 Aug 16 [cited 2022 Feb 23]; [about 5p.]. Available at: https://salud.msp.gob.cu/variante-delta-desafios-e-incertidumbres-ante-mayor-incidencia-de-covid-19/. Spanish.

  11. Portal Miranda JA. Health intervention withvaccine candidates as a temporary strategy toconfront COVID-19, Cuba, 2021. Rev CubanaSalud Pública [Internet]. 2021 Jan 5 [cited 2022Feb 23];48(1):e3513. Available at: http://www.revsaludpublica.sld.cu/index.php/spu/article/view/3513. Spanish.

  12. Ministry of Public Health (CU) [Internet]. Havana:Ministry of Public Health (CU); c2022. Noticias.Nota informativa del Ministerio de Salud Pública.2021 Nov 29 [cited 2022 Feb 13]; [about 1p.]. Available at: https://salud.msp.gob.cu/nota-informativa-del-ministerio-de-salud-publica/.Spanish.

  13. Ministry of Public Health (CU) [Internet]. Havana:Ministry of Public Health (CU); c2022 Noticias.Ministro de Salud: Es imprescindible reforzarlas medidas para proteger el país; 2021 Dec30 [cited 2022 Feb 23]; [about 4 p.]. Availableat: https://salud.msp.gob.cu/es-imprescindible-reforzar-las-medidas-para-proteger-el-pais/.Spanish.

  14. Center for Disease Control and Prevention. Protocolsfor SARS-CoV-2 sequencing [Internet].California: Pacifi c Biosciences of California; 2020[cited 2022 Feb 23]. 7 p. Available at: https://www.pacb.com/wp-content/uploads/Customer-Collaboration-PacBio-Compatible-CDC-Protocols-for-SARS-CoV-2-Sequencing.pdf

  15. Global Initiative on Sharing All Infl uenza Data(GISAID) [Internet]. Munich: Global Initiative onSharing All Infl uenza Data (GISAID); c2008–2022. CoVsurver: Mutation Analysis of hCoV-19;2021 [cited 2022 Jan 20]. Available at: https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/

  16. World Health Organizatioon [Internet]. Geneva:World Health Organization; c2022. Publications.Overview. Living guidance for clinical managementof COVID-19; 2021 Nov 23 [cited 2022Feb 23]; [2.4 MB]. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2

  17. Ministry of Public Health (CU) [Internet]. Havana:Ministry of Public Health (CU); c2022. Candidatosvacunales. Actualización de la estrategia parael desarrollo de las vacunas cubanas; [cited 2022Jul 29]; [about 6 p.]. Available at: https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/.Spanish

  18. Reported Cases and Deaths by Country orTerritory [Internet]. [place unknown]: Worldometers;2022 [cited 2022 March 7]; [about10 p.]. Available at: www.worldometers.info/coronavirus/#countries

  19. Ministry of Public Health (CU) [Internet]. Havana:Ministry of Public Health (CU); c2022. Noticias.Nota informativa del Ministerio de Salud Pública. 2021 Dec 15 [cited 2022 Feb 26]. Available at:https://salud.msp.gob.cu/nota-informativa-del-ministerio-de-salud-publica-3/. Spanish.

  20. CDC COVID-19. SARS-CoV-2 B.1.1.529 (Omicron)Variant - United States, December 1-8,2021. MMWR Morb Mortal Wkly Rep. 2021 Dec17;70(50):1731–4. https://doi.org/10.15585/mmwr.mm7050e1

  21. Network of Genomic Surveillance in South Africa(NGS-SA). SARS-CoV-2 Sequencing Update 26November 2021 [Internet]. Durban: Network ofGenomic Surveillance in South Africa (NGS-SA),Nelson R. Mandela School of Medicine; 2021[cited 2022 Feb 14]. 28 p. Available at: https://www.nicd.ac.za/wp-content/uploads/2021/11/Update-of-SA-sequencing-data-from-GISAID-26-Nov_Final.pdf

  22. Fall A, Eldesouki RE, Sachithanandham J, PaulMorris C, Norton JM, Gaston DC, et al. A quickdisplacement of the SARS-CoV-2 variant Deltawith Omicron: unprecedented spike in COVID-19cases associated with fewer admissions andcomparable upper respiratory viral loads. medRxiv[Preprint]. 2022 Jan 28. 2022.01.26.22269927.https://doi.org/10.1101/2022.01.26.22269927

  23. Mohapatra RK, Tiwari R. Twin combination ofOmicron and Delta variants triggering a tsunamiwave of ever high surges in COVID-19 cases:a challenging global threat with a special focuson the Indian subcontinent. J Med Virol. 2022May;94(5):1761–5. https://doi.org/10.1002/jmv.27585

  24. Ministry of Public Health (CU) [Internet]. Havana:Ministry of Public Health (CU); c2022. Candidatosvacunales. Actualización de la estrategia parael desarrollo de las vacunas cubanas; [cited 2022June 3]; [about 6 p.]. Available at: https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/.Spanish.

  25. Our World in Data [Internet]. Oxford: GlobalChange Data Lab; c2022. Coronavirus. Vaccinations.Coronavirus (COVID-19) Vaccinations;[cited 2022 May 30]; [about 10 p.]. Available at:https://ourworldindata.org/covid-vaccinations

  26. Garrett N, Tapley A, Andriesen J, Seocharan I,Fisher LH, Bunts L, et al. High rate of asymptomaticcarriage associated with variantstrain Omicron. medRxiv [Preprint]. 2022 Jan14;2021.12.20.21268130. https://doi.org/10.1101/2021.12.20.21268130

  27. Piersiala K, Kakabas L, Bruckova A, StarkhammarM, Cardell LO. Acute odynophagia - a newsymptom of COVID-19 during the SARS-CoV-2Omicron variant wave in Sweden. J Intern Med.2022 Jul;292(1):154–61. https://doi.org/10.1111/joim.13470

  28. Kahn F, Bonander C, Moghaddassi M, RasmussenM, Malmqvist U, Inghammar M, et al. Riskof severe COVID-19 from the Delta and Omicronvariants in relation to vaccination status, sex,age and comorbidities - surveillance results fromsouthern Sweden, July 2021 to January 2022.Euro Surveill. 2022 Mar;27(9):2200121. https://doi.org/10.2807/1560-7917.es.2022.27.9.2200121

  29. Vanshylla K, Tober-Lau P, Gruell H, Münn F,Eggeling R, Pfeifer N, et al. Durability of omicronneutralisingserum activity after mRNA boosterimmunisation in older adults. Lancet Infect Dis.2022 Apr;22(4):445–6. https://doi.org/10.1016/s1473-3099(22)00135-9




2020     |     www.medigraphic.com